{"id":"NCT02367820","sponsor":"Nektar Therapeutics","briefTitle":"Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain","officialTitle":"A Phase 3 Multicenter, Open-Label, 52-Week Study To Evaluate the Long-Term Safety and Tolerability of NKTR-181 in Subjects With Moderate to Severe Chronic Low Back Pain or Chronic Non-Cancer Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04-14","primaryCompletion":"2017-12","completion":"2018-01","firstPosted":"2015-02-20","resultsPosted":"2020-10-08","lastUpdate":"2021-06-22"},"enrollment":638,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Low Back Pain","Chronic Pain"],"interventions":[{"type":"DRUG","name":"NKTR-181 BID tablets","otherNames":[]}],"arms":[{"label":"NKTR-181","type":"EXPERIMENTAL"}],"summary":"The purpose of this 52-week open label study is to determine the long-term safety of a new opioid molecule, NKTR-181, in patients with moderate to severe chronic low back pain or chronic non-cancer pain.","primaryOutcome":{"measure":"Number of Participants Reporting Adverse Events","timeFrame":"Screening baseline through end of study, an average of 57 weeks","effectByArm":[{"arm":"Rollover NKTR-181","deltaMin":138,"sd":null},{"arm":"Rollover PBO","deltaMin":151,"sd":null},{"arm":"De Novo Opioid Experienced","deltaMin":110,"sd":null},{"arm":"De Novo Naive","deltaMin":62,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":56,"countries":["United States"]},"refs":{"pmids":["31361019","30957581"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":214},"commonTop":["Constipation","Nausea","Headache","Upper respiratory tract infection","Drug withdrawal"]}}